Literature DB >> 28077671

Impact of long-term care facility residence on the antibiotic resistance of urinary tract Escherichia coli and Klebsiella.

Alicia Rosello1,2, Andrew C Hayward2, Susan Hopkins3,4, Carolyne Horner5, Dean Ironmonger6, Peter M Hawkey7,8, Sarah R Deeny9,10.   

Abstract

Background: Long-term care facilities (LTCFs) are thought to be important reservoirs of antimicrobial-resistant (AMR) bacteria; however, there is no routine surveillance of resistance in LTCF residents, or large population-based studies comparing AMR in LTCFs with the community, so the relative burden of AMR in LTCFs remains unknown.
Objectives: To compare the frequency of antibiotic resistance of urinary tract bacteria from residents of LTCFs for the elderly and adults aged 70 years or older living in the community.
Methods: Positive urine specimens reported to any diagnostic microbiology laboratory in the West Midlands region (England) from 1 April 2010 to 31 March 2014 collected from individuals aged 70 years or older were analysed. The resistance of Escherichia coli and Klebsiella to trimethoprim, nitrofurantoin, third-generation cephalosporins and ciprofloxacin and the rate of laboratory-confirmed E. coli and Klebsiella urinary tract infection (UTI) were assessed in LTCF residents and in the community.
Results: LTCF residents had a laboratory-confirmed E. coli and Klebsiella UTI rate of 21 per 100 person years compared with 8 per 100 person years in the elderly living in the community [rate ratio (RR)=2.66, 95% CI = 2.58-2.73] and a higher rate of developing E. coli and Klebsiella UTIs caused by bacteria resistant to trimethoprim (RR = 4.41, 95% CI = 4.25-4.57), nitrofurantoin (RR = 4.38, 95% CI = 3.98-4.83), ciprofloxacin (RR = 5.18, 95% CI = 4.82-5.57) and third-generation cephalosporins (RR = 4.49, 95% CI = 4.08-4.94). Conclusions: Residents of LTCFs for the elderly had more than double the rate of E. coli and Klebsiella UTI and more than four times the rate of E. coli and Klebsiella UTI caused by antibiotic-resistant bacteria compared with those living in the community.
© The Author 2017. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Mesh:

Year:  2017        PMID: 28077671     DOI: 10.1093/jac/dkw555

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  5 in total

1.  Antimicrobial resistance in urinary pathogens and culture-independent detection of trimethoprim resistance in urine from patients with urinary tract infection.

Authors:  Yinka M Somorin; Nichola-Jane M Weir; Sally H Pattison; Martin A Crockard; Carmel M Hughes; Michael M Tunney; Deirdre F Gilpin
Journal:  BMC Microbiol       Date:  2022-05-24       Impact factor: 4.465

2.  Changes of antibiotic prescribing pattern and its resistance to E. Coli in South Korea: a 12-year retrospective observational study.

Authors:  Geun Woo Lee; Sukhyun Ryu; Juhee Park; Eun Jee Lee; Kwang Jun Lee; Jungyeon Tae; Youngsik Hwang; Dong-Sook Kim
Journal:  Sci Rep       Date:  2021-03-11       Impact factor: 4.379

3.  Antimicrobial prescribing in long-term care facilities: a nationwide point-prevalence study, Slovenia, 2016.

Authors:  Dora Stepan; Lea Ušaj; Marija Petek Šter; Marjetka Smolinger Galun; Hermina Smole; Bojana Beović
Journal:  Euro Surveill       Date:  2018-11

4.  Resistome and Virulome of Multi-Drug Resistant E. coli ST131 Isolated from Residents of Long-Term Care Facilities in the Northern Italian Region.

Authors:  Sabrina Cherubini; Mariagrazia Perilli; Anna Maria Azzini; Evelina Tacconelli; Laura Maccacaro; Alda Bazaj; Laura Naso; Gianfranco Amicosante; Giuliana Lo Cascio; Alessandra Piccirilli
Journal:  Diagnostics (Basel)       Date:  2022-01-16

5.  Clinical impact of multidrug-resistant bacteria in older hospitalized patients with community-acquired urinary tract infection.

Authors:  Manuel Madrazo; Ana Esparcia; Ian López-Cruz; Juan Alberola; Laura Piles; Alba Viana; José María Eiros; Arturo Artero
Journal:  BMC Infect Dis       Date:  2021-12-07       Impact factor: 3.090

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.